Workshop Summary: Introduction to Rational Design of New Means for Therapeutic Modulation of Function of the TNF Family
The conference session entitled “Rational Design of New Means for Therapeutic Modulation of Function of the TNF Family,” as the title implies, explored multiple novel strategies to develop new drugs acting as agonists and antagonists of the TNF–TNFR superfamily for treatment of cancer and chronic or acute inflammatory diseases, respectively. The approved clinical use of agonistic superfamily ligands in cancer therapy is presently restricted to TNF itself, used in a few selected indications that allow locoregional application (e.g., isolated limb perfusion).
KeywordsLymphoma Tuberculosis Etanercept Tace Prolia
- 1.(2008) Top 20 Biologics - 2008 Sales of Antibodies & Proteins. In R&D Pipeline News, La Merie Business Intelligence (article dated March 9, 2009, available at http://www.pipelinereview.com.)
- 5.Olleros ML et al (2009) Dominant-negative tumor necrosis factor protects from Mycobacterium bovis Bacillus Calmette-Guérin(BCG) and endotoxin-induced liver injury without compromising host immunity to BCG and Mycobacterium tuberculosis. J Inf Dis 199 (7):1109–1120Google Scholar